Revolutionizing Antibody Development: MabGenesis Inc. Secures $3.2M Funding

MabGenesis Inc., a pioneering biopharmaceutical company renowned for its innovative approach to therapeutic antibodies, is thrilled to announce a successful funding round, raising $3.2 million. This significant investment marks a crucial step forward for MabGenesis, which specializes in developing fully species-specific therapeutic antibodies for both human and companion animals. Leveraging our industry-leading MOURA Libraries, which are celebrated for their unparalleled quality in functionality and completeness, alongside our cutting-edge monoclonal antibody isolation technology, IMPACT, we are uniquely positioned to address the increasing demand for high-affinity monoclonal antibodies. These capabilities enable us to target unique 3D structures and subtle structural differences of various molecules, including complex membrane proteins, unlocking new avenues for drug development in the pharmaceutical sector. The funding will be strategically allocated to accelerate our research and development initiatives, enhance our antibody libraries, and expedite the commercialization of our innovative products. We are excited to continue our mission in revolutionizing therapeutic solutions while improving health outcomes for both humans and animals. This investment not only underscores the confidence investors have in MabGenesis but also reinforces our commitment to driving forward the future of biopharmaceuticals. With this new support, we look forward to advancing our novel therapies and making a lasting impact on the global healthcare landscape.